These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24253314)

  • 1. Cognitive factors associated with adherence to oral antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study.
    Klepin HD; Geiger AM; Bandos H; Costantino JP; Rapp SR; Sink KM; Lawrence JA; Atkinson HH; Espeland MA
    Cancer Prev Res (Phila); 2014 Jan; 7(1):161-8. PubMed ID: 24253314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene.
    Legault C; Maki PM; Resnick SM; Coker L; Hogan P; Bevers TB; Shumaker SA
    J Clin Oncol; 2009 Nov; 27(31):5144-52. PubMed ID: 19770382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial.
    Danhauer SC; Legault C; Bandos H; Kidwell K; Costantino J; Vaughan L; Avis NE; Rapp S; Coker LH; Naughton M; Naylor C; Terracciano A; Shumaker S
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2013; 20(5):532-52. PubMed ID: 23237718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition.
    Espeland MA; Shumaker SA; Limacher M; Rapp SR; Bevers TB; Barad DH; Coker LH; Gaussoin SA; Stefanick ML; Lane DS; Maki PM; Resnick SM
    J Womens Health (Larchmt); 2010 Mar; 19(3):371-9. PubMed ID: 20136553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
    JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
    Vogel VG
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):51-60. PubMed ID: 19105706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of breast cancer in postmenopausal women.
    Geller BA; Vogel VG
    Breast Dis; 2005-2006; 24():79-92. PubMed ID: 16917141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
    Nelson HD; Smith ME; Griffin JC; Fu R
    Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer chemoprevention: current clinical practice and future direction.
    Bevers TB
    Biomed Pharmacother; 2001 Nov; 55(9-10):559-64. PubMed ID: 11769967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
    Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
    J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
    Fagerlin A; Dillard AJ; Smith DM; Zikmund-Fisher BJ; Pitsch R; McClure JB; Greene S; Alford SH; Nair V; Hayes DF; Wiese C; Ubel PA
    Breast Cancer Res Treat; 2011 Jun; 127(3):681-8. PubMed ID: 21442198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
    Runowicz CD; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Ford LG; Vogel VG; Wolmark N
    Am J Obstet Gynecol; 2011 Dec; 205(6):535.e1-5. PubMed ID: 21872200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
    Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
    J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration.
    Kara F; Lohse CM; Castillo AM; Tosakulwong N; Lesnick TG; Jack CR; Petersen RC; Olson JE; Couch FJ; Ruddy KJ; Kantarci K; Mielke MM
    Cancer Med; 2023 Feb; 12(3):2805-2817. PubMed ID: 36040183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
    Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
    Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer.
    Boele FW; Schilder CM; de Roode ML; Deijen JB; Schagen SB
    Menopause; 2015 Jan; 22(1):17-25. PubMed ID: 24977455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.